Biocon Limited (BOM:532523)
India · Delayed Price · Currency is INR 388.25
-21.90 (-5.34%)
At close: Dec 4, 2025
Biocon Revenue
Biocon had revenue of 42.96B INR in the quarter ending September 30, 2025, with 19.64% growth. This brings the company's revenue in the last twelve months to 164.76B, up 10.62% year-over-year. In the fiscal year ending March 31, 2025, Biocon had annual revenue of 152.62B with 3.43% growth.
Revenue (ttm)
164.76B
Revenue Growth
+10.62%
P/S Ratio
3.18
Revenue / Employee
10.10M
Employees
16,315
Market Cap
523.98B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 152.62B | 5.06B | 3.43% |
| Mar 31, 2024 | 147.56B | 35.82B | 32.05% |
| Mar 31, 2023 | 111.74B | 29.90B | 36.54% |
| Mar 31, 2022 | 81.84B | 10.41B | 14.57% |
| Mar 31, 2021 | 71.43B | 8.43B | 13.37% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 10.00T |
| Life Insurance Corporation of India | 9.14T |
| State Bank of India | 3.57T |
| Larsen & Toubro | 2.76T |
| HDFC Bank | 2.68T |
| Tata Consultancy Services | 2.58T |
| Bharti Airtel | 1.95T |
| ICICI Bank | 1.91T |
Biocon News
- 4 days ago - Biocon Biologics secures market pathway for Denosumab Biosimilars in Europe following settlement with Amgen - Business Upturn
- 11 days ago - Going bananas for Bengaluru’s road safety: Kiran Mazumdar-Shaw’s compliment sparks buzz on X - The Times of India
- 16 days ago - Biocon shares fall sharply over 3% as Citi downgrades stock to ‘Sell’ with target price to Rs 360 - Business Upturn
- 17 days ago - Biocon subsidiary gets U.S. FDA approval for Tofacitinib Extended-Release tablets - Business Upturn
- 22 days ago - Biocon clarifies on merger speculation, says committee still evaluating restructuring options - Business Upturn
- 22 days ago - US Proposal Could Halve Biocon's Biosimilar Development Costs - NDTV
- 23 days ago - Biocon shares surge over 3% today on strong Q2 performance: Should you buy the stock? — explained - Business Upturn
- 23 days ago - Biocon MD says board has not taken any action on Biocon Biologics merger yet: Report - Business Upturn